Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20 monoclonal antibody BAT4306F

A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BAT 4306F
BAT-4306F
BAT4306F
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search